Vor Bio price target lowered to $18 from $27 at Oppenheimer

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Vor Bio to $18 from $27 and keeps an Outperform rating on the shares following quarterly results. The analyst still believes the stock is trading at a significant discount ahead of first-in-human results from VOR33-and still believes the main reason for this is investor blase toward the field of stem cell transplantation. He hopes this changes, because Biegler sees VOR33 as real opportunities to fundamentally alter the treatment of AML.